Health Economic Analysis Reports That Revlimid is a Cost Effective - ForbesCelgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID Source: www.forbes.com
Blood test may detect cancer - [...]

continue reading.....